Predictive value of MMP‐7 expression for response to chemotherapy and survival in patients with non‐small cell lung cancer
Authors:
Open Access
- 3 November 2008
- journal article
- Published by Wiley in Cancer Science
- Vol. 99 (11) , 2185-2192
Abstract
Fundamental studies have suggested that matrix metalloproteinases‐7 (MMP‐7) expression is associated with chemoresistance and constitutes a prognostic factor in several solid tumors. The present study assessed the prognostic and predictive value of MMP‐7 in tumors of patients with advanced non‐small cell lung cancer (NSCLC) treated with platinum‐based chemotherapy. In total, 159 patients with stage III and IV NSCLC were retrospectively enrolled. Immunohistochemistry was performed to evaluate the expression of MMP‐7, apoptosis‐related proteins Bcl‐2, Bax, Fas and FasL and the Ki‐67 proliferation marker. The TUNEL (terminal deoxynucleotidyl transferase‐mediated deoxyuridine triphosphate nick‐end labeling) method was performed to investigate tumor apoptosis. Ninety carcinomas (56.6%) were identified as high expression of MMP‐7. Overexpression of MMP‐7 was more frequent in adenocarcinomas than in squamous cell carcinomas (P = 0.032). The expression of MMP‐7 was positively related with Ki‐67 index and Bcl‐2, but not apoptosis index. MMP‐7 status was correlated inversely with response to chemotherapy in overall patients (response rates, 20.0% and 35.8%, for patients with high‐MMP‐7 and low‐MMP‐7 tumors, respectively, P = 0.036), especially in adenocarcinoma (P = 0.021), but not in patients with squamous cell carcinomas (P = 0.373). The overall survival was significantly lower in NSCLC patients with high MMP‐7 than in those with low MMP‐7 (P < 0.001). A Cox regression analyses also demonstrated MMP‐7 status to be a significant prognostic factor (hazard ratio, 5.49; P = 0.001). These findings suggest that the expression level of MMP‐7 in tumor cells is predictive of response to chemotherapy and outcome in patients with advanced NSCLC receiving platinum‐based chemotherapy. (Cancer Sci 2008; 99: 2185–2192)Keywords
This publication has 36 references indexed in Scilit:
- Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancerLung Cancer, 2007
- Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxelAnti-Cancer Drugs, 2007
- Matrix Metalloproteinases in Lung: Multiple, Multifarious, and MultifacetedPhysiological Reviews, 2007
- Expression of Matrix Metalloproteinase-7 on Cancer Cells and Tissue Endothelial Cells in Renal Cell Carcinoma: Prognostic Implications and Clinical Significance for Invasion and MetastasisClinical Cancer Research, 2006
- Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancerLung Cancer, 2006
- Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK–ERK signal transduction pathwayJournal of Clinical Pathology, 2005
- Proliferative effects of apical, but not basal, matrix metalloproteinase-7 activity in polarized MDCK cellsExperimental Cell Research, 2005
- Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cellsOncogene, 2004
- Extracellular matrix regulation of drug resistance in small-cell lung cancerClinical Science, 2002
- CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodelingGenes & Development, 2002